Q-omics provides the consensus-scored BPIFB6 profile across patient tissues and cancer cell-line models. BPIFB6 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, BPIFB6 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, BPIFB6 RNA expression shows 6,435 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, BRCA, and STAD as cancer lineages where BPIFB6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BPIFB6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BPIFB6 survival associations across molecular data types. BPIFB6 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BPIFB6 RNA expression–survival associations across cancer types. High BPIFB6 expression shows unfavorable associations in CESC, UVM, KIRC, UCS, SCLC and KIRP. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify CESC as the clearest survival context for BPIFB6 RNA expression.
This table summarizes BPIFB6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for BPIFB6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BPIFB6 shows lower tumor expression in HNSC and higher tumor expression in BRCA, KIRC and LUAD. The BRCA box plot shows higher BPIFB6 RNA expression in tumor versus normal tissue (log2 FC = +0.112, t-test p = .001).
This table shows molecular features associated with BPIFB6 in patient tissues and cancer cell lines. In patient samples, BPIFB6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, BPIFB6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
